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VirusRegulated intramembrane proteolysis (RIP) is a signaling mechanism through which transmembrane
precursor proteins are cleaved to liberate their cytoplasmic and/or luminal/extracellular fragments from
membranes so that these fragments are able to function at a new location. Recent studies have indicated
that this proteolytic reaction plays an important role in host–virus interaction. On one hand, RIP transfers
the signal from the endoplasmic reticulum (ER) to nucleus to activate antiviral genes in response to alteration
of the ER caused by viral infection. On the other hand, RIP can be hijacked by virus to process transmembrane
viral protein precursors and to destroy transmembrane antiviral proteins. Understanding this Yin and Yang
side of RIP may lead to new strategies to combat viral infection. This article is part of a Special Issue entitled:
Intramembrane Proteases.
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There is growing evidence indicating that membrane proteins can
be cleaved within the plane of the membrane. Such cleavage liberatesembrane Proteases.
l rights reserved.cytoplasmic and/or luminal/extracellular fragments of transmem-
brane precursor proteins and allows these fragments to function at
a new location. This mechanism, termed regulated intramembrane
proteolysis (RIP), inﬂuences processes as diverse as cellular differen-
tiation, lipid metabolism, and the response to unfolded proteins [1].
Three classes of protease, namely Site-2 protease (S2P), rhomboid,
and aspartyl intramembrane proteases, are known to catalyze the
intramembrane cleavage [2]. Aspartyl intramembrane proteases are
a large family of proteins that include γ-secretase, signal peptide
peptidase (SPP), and SPP-like proteins (SPPLs) [3]. Emerging evidence
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action during viral infection.
Infection ofmammalian cells by almost all classes of virus induces en-
doplasmic reticulum (ER) stress by massive synthesis of ER-associated
viral proteins [4]. Viral infection also frequently leads to alteration in
the ER structure to generate membrane vesicles that protect the viral
replication machinery [5]. Thus, the signaling pathway transmitting the
signal generated through changes in the ER caused by viral infection to
nucleus where genes combating viral infection are activated should be
important for antiviral immunity. Indeed, recent studies have pointed
out the importance of S2P-catalyzed RIP, which plays a critical role to
transfer signal from the ER to nucleus [2], in antiviral immunity [6–8].
In addition to S2P, SPP and SPPL-mediated RIP has also been
reported to mediate virus–host interactions. RIP catalyzed by these
proteases regulates functions of immune cells [9–11]. Nevertheless,
SPP has also been shown to be hijacked by virus to facilitate the
progression of its life cycle. The protease is used by several viruses
to process the viral protein precursors and to degrade transmem-
brane proteins involved in antiviral immune responses [12–14].
This article will discuss the RIP process that plays an important
role in antiviral immunity as well as that facilitates viral infection.2. Host–virus interactions mediated by S2P-catalyzed RIP
2.1. Overview of S2P-catalyzed RIP
S2P is a polytopic membrane protein with the characteristics of
a membrane-embedded zinc metalloprotease [15]. The protease
cleaves transcription factors synthesized as membrane-bound pre-
cursors [2]. Cleavage mediated by S2P is tightly coupled to proteolysis
catalyzed by Site-1 protease (S1P): The S2P-catalyzed cleavage does
not take place until the bulk of the luminal portion of the RIP sub-
strates has been removed by S1P-mediated proteolysis, as a short lu-
minal segment is a prerequisite for S2P-catalyed intramembrane
cleavage [16–18]. Notably, S1P also cleaves protein precursors of
Lassa virus and Crimean–Congo hemorrhagic fever virus to produce
mature viral surface glycoproteins that are required for viral infection
[19,20]. However, since these cleavages only require S1P but not S2P,
they should not be categorized as RIP.
The most extensively studied proteins cleaved by S2P are sterol
regulatory element binding proteins (SREBPs), a family of transcrip-
tion factors critical for regulation of cholesterol metabolism [21,22].
SREBPs are inserted in membranes of the endoplasmic reticulum
(ER) through two transmembrane helices in a hairpin fashion with
both the NH2- and COOH-terminal of the protein facing the cytosol.
In cells deprived of cholesterol, SREBPs are transported from the ER
to Golgi complex where the proteins are cleaved by S1P followed by
S2P, both of which are Golgi-resident proteins [23,24]. This cleavage
releases the NH2-terminal domain of SREBPs from membranes,
allowing them to activate all genes required for cholesterol synthesis
and uptake in nucleus [22]. Accumulation of cholesterol in the ER
causes SREBPs to be trapped in the ER so that they are separated
from S1P and S2P [25]. Consequently, SREBPs are not proteolytically
activated, resulting in declination of transcription of genes required
for cholesterol synthesis and uptake.
Another well-characterized transcription factor proteolytically
activated by S2P is activation transcription factor 6 (ATF6). ATF6 is a
type II membrane protein with a single transmembrane domain
[26]. The NH2-terminal domain of the protein faces cytosol [26].
Under resting condition, ATF6 is not cleaved as it is retained in the
ER [27]. Upon accumulation of unfolded proteins in the ER, ATF6 is
translocated from the ER to Golgi, where it is cleaved sequentially
by S1P and S2P [17,27,28]. The intramembrane proteolysis carried
out by S2P liberates the NH2-terminal domain of ATF6 from mem-
branes, allowing it to enter nucleus where it activates transcriptionof chaperons that facilitate protein folding in the ER [26]. This regula-
tory pathway helps cells to survive conditions of ER stress.
RIP of SREBPs and AFT6 plays important roles for viral infection,
but the effect is indirectly related to cholesterol metabolism and ER
stress. Thus, it will not be further discussed in this article. Instead,
two RIP reactions catalyzed by S1P and S2P that directly counter
viral infections will be discussed in detail below.
2.2. Antiviral responses mediated by RIP of cAMP response element binding
protein 3-like 1 (CREB3L1)
Similar to ATF6, CREB3L1 (also known as OASIS) contains a single
transmembrane helix with the NH2-terminal cytosolic domain re-
sembling a transcription factor of the basic leucine zipper family
[29]. CREB3L1 has been reported to stimulate synthesis of collagen
required for bone formation [30]. The ﬁrst clue that CREB3L1 may
be involved in antiviral responses came from the observation that
infection of West Nile virus reduced the amount of this protein in
neurons [31]. The importance of CREB3L1 in antiviral immunity has
been subsequently recognized through observations that expression
of the protein has to be silenced in cells permissive for hepatitis
C virus (HCV) replication [7,32].
HCV is a positive stranded RNA virus accounting for most cases of
chronic liver disease worldwide and is the major risk factor for devel-
opment of hepatocarcinoma [33,34]. The replication of HCV in
cultured cells was ﬁrst studied through HCV subgenomic replicon,
which consists of HCV RNA engineered to express a selectable marker
gene, neo, in place of a portion of the viral RNA that is not required for
viral replication [35]. WhenHuh7 cells, a line of human hepatoma cells,
were transfected with the HCV subgenomic replicon followed by selec-
tion with G418, subclones of Huh7 cells were established in which HCV
RNAwas constantly replicating [35]. However, only a few cells survived
the selection, an observation suggesting that Huh7 cells are not very
permissive for HCV replication [35,36]. When HCV RNAwas eliminated
from the cells harboring theHCV replicon through interferon treatment,
the cured cells showed dramatically enhanced permissiveness for HCV
RNA replication as demonstrated by the large number of cells that
survived G418 selection following re-transfection with the HCV repli-
con RNA [36]. Thus, transfection of HCV replicon followed by G418
treatment selected a small population of Huh7 cells permissive for
HCV replication [32]. Compared to their parental Huh7 cells, expression
of CREB3L1 protein is dramatically reduced in various independent
subclones of Huh7 cells permissive for HCV replication [7,32].
Further studies revealed that HCV infection triggered sequential
cleavage of CREB3L1 catalyzed by S1P and S2P [7] (Figs. 1 and 2).
The S2P-catalyzed ﬁnal cleavage liberates the NH2-terminal domain
of CREB3L1 from membranes, allowing it to activate genes encoding
cell cycle inhibitors to block proliferation of the virus-infected cells
[7] (Figs. 1 and 2). Inasmuch as HCV replication in Huh7-derived cells
requires active division of the host cells [37,38], RIP of CREB3L1 not
only blocks proliferation of HCV-infected cells but also inhibits viral
replication [7]. These results explain why expression of CREB3L1 has
to be silenced in subclones of Huh7 cells permissive for HCV replication,
as these cells have to divide in the presence of efﬁcient replication of the
viral RNA.
The effect of CREB3L1 on cell proliferation is not restricted to
HCV-infected cells. Infection with other RNA virus such as West Nile
and Sendai virus and DNA virus such as murine γ-herpesvirus 68
also triggered RIP of CREB3L1, resulting in blockage in proliferation
of the cells infected by the virus [7]. Thus, CREB3L1 may play an
important role to prevent viral spreading by inhibiting proliferation
of virus-infected cells, and the protein may be particularly effective
in combating infection of virus whose replication depends on active
division of the host cells. While replication of HCV in cultured cells
requires proliferation of the host cells [37,38], such requirement in
virus-infected patients remains to be determined. The best studied
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human papillomavirus (HPV) [39], a DNA virus that is a predominant
risk factor for development of cervical and oropharyngeal cancers
[40]. Therefore, CREB3L1 could be a major obstacle for HPV infection.
To overcome this obstacle, HPV is likely to develop strategies to inac-
tivate CREB3L1. HPV is known to encode viral proteins that inhibit
cellular proteins controlling progression of cell cycle [39]. One of the
viral proteins E5, which stimulates cell cycle progression [39], is aCell Cycle
Inhibitors
ER
C
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Fig. 2. Viral infection-induced RIP of CREB3L1. Viral infection-induced production of ceram
may stimulate translocation of CREB3L1 precursor from the ER to Golgi, where the protein is
CREB3L1 from membranes, allowing it to enter the nucleus where it activates genes encodtransmembrane protein located in the ER and Golgi complex [41]. Con-
sidering that ER to Golgi translocation is required for transmembrane
precursor proteins to be proteolytically activated by S2P-catalyzed
RIP, E5 may be an inhibitor for RIP of CREB3L1. If so, relieving this inhi-
bition could be a novel strategy to treat HPV infection.
Inasmuch as CREB3L1 activates multiple genes encoding inhibitors
of cell cycle, the protein may be considered as a tumor suppressor.
Further evidence supporting this notion came from the observationG
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ide and/or ER stress caused by massive synthesis of virus-encoded membrane proteins
sequentially cleaved by S1P and S2P. This cleavage releases the NH2-terminal domain of
ing cell cycle inhibitors to block proliferation of the virus-infected cells.
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chemotherapeutic reagent, to block proliferation of cancer cells [42],
and the observation that inactivation of CREB3L1 through chromosome
fusion is associated with development of low-grade ﬁbromyxoid
sarcoma [43]. Considering that CREB3L1 is proteolytically activated
in virus-infected cells, the protein may play an important role in
preventing virus-induced tumorigenesis. If this is indeed the case,
tumors induced by viral infection may have impaired RIP of CREB3L1
and consequently become resistant to doxorubicin treatment. Thus,
understanding the role of CREB3L1 in virus-induced tumor formation
may provide more insight into selection of chemotherapeutic reagents
to treat these tumors.
It remains unclear how viral infection triggers RIP of CREB3L1. It
was reported previously that ER stress triggers cleavage of CREB3L1
[44]. Since viral infection is known to induce ER stress through
massive synthesis of ER-associated viral protein [4], it is possible
that viral infection triggers cleavage of CREB3L1 through ER stress
(Fig. 2). Viral infection was also known to trigger production of
ceramide [45,46]. Inasmuch as ceramide is a potent stimulator for
RIP of CREB3L1 [42], viral infection-induced accumulation of cer-
amide may also be involved in stimulating RIP of CREB3L1 (Fig. 2).
2.3. Antiviral responses mediated by RIP of CREB3
CREB3 (also known as Lzip and Luman), which adopts a membrane
topology similar to that of CREB3L1, is another transcription factor acti-
vated through RIP catalyzed by S1P and S2P [47]. Similar to CREB3L1,
CREB3 may also be involved in inhibition of cell cycle, as loss of CREB3
function triggers transformation of NIH-3T3 cells [48]. Expression of
HCV core protein stimulates transformation of the cells by excluding
CREB3 from nucleus [48]. While the mechanism of this reaction has
not been identiﬁed, it is likely that core protein inhibits RIP of CREB3.
However, it should be noted that cellular transformation caused by
core-mediated inhibition of CREB3was observed in cells overexpressing
the viral core protein alone but not in those infected by HCV [48]. Thus,
the contribution of core-mediated inactivation of CREB3 inHCV-induced
hepatocarcinoma remains unclear.
The CREB3-mediated antiviral response has been best illustrated
by its activity in inhibiting infection of human immunodeﬁciency
virus (HIV), a retrovirus [6]. HIV envelope glycoprotein (Env) is syn-
thesized as a 160 kDa precursor and is processed during its passage
through the secretory pathway by a host cell protease, furin, to
produce the extracellular subunit (gp120) and the transmembrane
subunit (gp41) [49]. CREB3 was identiﬁed as a protein that binds to
gp41, and this interaction leads to degradation of CREB3 [6].
To determine the functional signiﬁcance of gp41-mediated degra-
dation of CREB3, the nuclear form of CREB3 corresponding to its
NH2-terminal domain was transfected to cells infected by HIV. The
result revealed that the cleaved nuclear form of CREB3 bound to
another HIV protein Tat that activates transcription of viral proteins
required for assembly of viral particles [6]. This interaction inhibited
the function of Tat, leading to reduced production of infectious viral
particles [6]. These observations suggest that RIP of CREB3 is likely
to be stimulated in response to retroviral infection in order to inhibit
assembly of viral particles by blocking the Tat activity (Fig. 1). To
counter this antiviral response, HIV uses gp41 subunit of its envelop
protein to stimulate degradation of CREB3 precursor. According to
this scenario, blocking the interaction between gp41 and CREB3
could be a novel strategy to treat HIV infection. Nevertheless, it
should be emphasized that RIP of CREB3 has never been observed in
HIV-infected cells owing to the rapid degradation of CREB3 precursor
in these cells.
CREB3 may also be involved in inhibition of lytic infection of
herpes simplex virus (HSV), a class of DNA virus [8]. Infection of
epithelial cells by HSV results in massive synthesis of viral genome
and infectious viral particles, eventually leading to death of the hostcells. This phase of the viral life cycle, which is referred as lytic infec-
tion, requires viral protein VP-16-activated transcription of viral
genes [50,51]. In order to activate its target gene, VP-16 has to bind
several host proteins including human factor C1 (HCF) [52]. The
membrane-bound CREB3 precursor was identiﬁed as a cellular
protein interacting with HCF [53,54]. This interaction retained HCF
in the ER, preventing HCF from entering the nucleus to facilitate tran-
scription activated by VP-16 [8]. As a result, cells overexpressing
CREB3 were resistant to lytic infection of HSV [8].
In addition to lytic infection, HSV can establish latent infection in
neurons within the trigeminal ganglia, during which only small por-
tions of the viral genome are transcribed [55]. The virus is quiescent
during latent infection but can be reactivated periodically to replicate
and move back along the axons to resume lytic infection in epithelial
cells [55]. It is proposed that high level of CREB3 expression in
neurons may suppress lytic infection by sequestering HCF in the ER
so that latent infection can be established in these cells [8]. According
to this hypothesis, RIP of CREB3 may trigger reactivation of HSV by
releasing HCF into the nucleus. Thus, identifying the conditions
activating RIP of CREB3 may lead to novel strategies to prevent
reactivation of HSV from latency.
RIP of CREB3 has been observed duringmaturation of dendritic cells,
the major antigen-presenting cells that play an important role in
antiviral adapt immunity [56,57]. However, the mechanism through
which CREB3 is proteolytic activated during dendritic cell maturation
and the physiological signiﬁcance of such activation remains unclear.
3. Host–virus interaction mediated by SPP and SPPLs
3.1. Overview of SPP and SPPLs
SPP and SPPLs are a family of membrane-embedded aspartic pro-
tease [3,58]. In mammalian cells, the family contains ﬁve members:
SPP, SPPL2a, SPPL2b, SPPL2c and SPPL3 [3]. Similar to S2P, SPP and
SPPLs cleave type II transmembrane protein, and in most cases the
proteolysis also requires a primary cleavage that removes bulk of
the protease substrates on the extracytoplasmic (luminal or extracel-
lular) side of the membranes [2]. While SPP locates in the ER, SPPL2a
and SPPL2b reside in endosomes, lysosomes and plasma membranes
[3]. The difference in their localization is consistent with the ﬁndings
that these proteases do not share the same substrates [3]. SPP and
SPPLs are involved in regulation of innate and adaptive immune
responses, but they can also be hijacked by viruses to facilitate the
progression of their life cycle (see Section 3.2–3.5).
3.2. SPP-catalyzed production of HLA-E ligand
The best-studied example of RIP mediated by SPP is the proteolytic
processing of signal peptides from major histocompatibility complex
(MHC) class I molecules such as HLA-A [9]. HLA-A is targeted to the se-
cretory pathway through its signal sequence. During its translocation
through the ER membrane, the signal sequence is cleaved off from the
pre-protein by signal peptidase. The cleaved signal peptide, which
remains membrane-bound with a type II orientation, is then cleaved
by SPP in the middle of the membrane to liberate the NH2-terminal
half of the signal peptide into the cytosol [9] (Fig. 1). This cytosolic frag-
ment is then transported into the ER lumen where it binds to HLA-E, a
nonclassical MHC class I molecule [59]. The HLA-E/peptide complexes
travel to the cell surface where they bind to CD94/NKG2A receptors
on natural killer (NK) cells and inhibit NK cell-mediated lysis [60].
This pathway protects cells expressing MHC class I molecules from
killing by NK cells.
Remarkably, this SPP-mediated pathway is hijacked by human
cytomegalovirus (HCMV) to protect virus-infected cells from NK
cell-induced cytotoxicity. HCMV, a DNA virus, encodes UL40 that
contains within its signal sequence a stretch of peptide identical to
2930 J. Ye / Biochimica et Biophysica Acta 1828 (2013) 2926–2932the ligand of HLA-E derived from signal sequence of the MHC class 1
molecules [61,62]. Following cleavage by signal peptidase, the signal
sequence of UL40 is further cleaved by SPP to produce the ligand for
HLA-E [63]. Enhanced presentation of HLA-E/peptide complex at the
cell surface protects the virus-infected cells from NK cell-mediated
lysis [62].
3.3. SPP-mediated degradation of MHC class I molecules in HCMV-infected
cells
HCMV is known to encode multiple proteins to evade the immune
system. In addition to UL40 as discussed in Section 3.2, HCMV also
encodes a viral protein US2 to stimulate degradation of MHC class I
molecules in order to hide viral infection from detection by the
immune system [64]. US2 triggers retrotranslocation of MHC class I
molecules from ER membranes to cytosol so that the proteins can
be degraded by proteasomes [64]. To identify the mechanism of the
US2-mediated evasion of the immune system, proteins associated
with wild type US2 were compared to those bound to a mutant inac-
tive form of the viral protein. This analysis identiﬁed SPP as a protein
interacting with wild type but not the mutant US2 [14]. Knockdown of
SPP blockedmembrane dislocation and subsequent proteasomal degra-
dation ofMHC class Imolecules in cells expressingUS2, indicating SPP is
involved in ER-associated degradation ofMHC class Imolecules induced
by the viral protein [14]. Importantly, SPP did not stimulate degradation
ofMHC class Imolecules in cells that did not express US2 [14]. Thus, this
process is completely different from SPP-mediated RIP of MHC class I
molecules (see Section 3.2) that takes place in cells free of viral infec-
tion. Indeed, it remains unclear whether the protease activity of SPP is
required for this process. SPP was found to be in two distinct com-
plexes: One contained signal peptides capable to be cleaved by SPP,
while the other one contained unfolded ER membrane proteins that
are not substrates for SPP but are destined for proteasomal degradation
[65,66]. Thus, SPP may not only cleave signal peptide but also partici-
pate in ER-associated degradation. Future studies are required to deter-
minewhether US2 recruits MHC class I molecules into the SPP complex
involved in proteasomal degradation of membrane proteins in the ER.
3.4. SPP-catalyzed maturation of HCV core protein
HCV encodes a polyprotein that is processed by viral and cellular
proteases to produce at least 10 viral proteins required for replicationCytosol
Lumen
ER
Core
Signal
Peptidase
Fig. 3. SPP-catalyzed maturation of HCV core protein. Signal peptidase cleaves HCV-encoded
sequence located at the COOH-terminal end of the core protein. This cleavage allows SPP to
be transported to lipid droplets where it is assembled into virus–lipoprotein particles.of viral RNA and assembly of viral particles [34]. The core protein corre-
sponds to the ﬁrst 169 amino acids of the viral polyprotein (Fig. 3). It is
localized at cytosolic side of the ER membrane and is linked to the re-
mainder of the viral protein via a signal peptide-like transmembrane se-
quence at its COOH terminus (Figs. 1 and 3). After cleavage by signal
peptidase in the ER lumen, SPP cleaves the signal peptide-like trans-
membrane domain [12,67,68] (Figs. 1 and 3). This cleavage liberates
the core protein from the ER, allowing it to associate with lipid droplets
where it assembles viral particles into a virus–lipoprotein complex
(Fig. 3) [12,69–72]. Consistent with these observations, inhibition of
SPP-catalyzed maturation of the core protein blocked production of
infectious HCV particles [68,73].
In addition to HCV, SPP is also required to process viral polyprotein
to produce the mature core protein in virus related to HCV, such as
classical swine fever virus and GB virus-B [13,74].
3.5. SPPL2a/b-catalyzed RIP of tumor necrosis factor α (TNFα) and foamy
virus envelope protein
SPPL2a and SPPL2b play an important role for activated dendritic
cells to induce T-helper 1 (Th1) cell-mediated antiviral adaptive immu-
nity. Upon activation by viral infection, dendritic cells produce TNFα, a
type 2 membrane protein [10] (Fig. 1). Following cleavage by TNFα
converting enzyme (TACE) that sheds the majority of the extracellular
domain, SPPL2a/b cleaves inside the transmembrane domain to release
the intracellular domain of TNFα from membranes, allowing it to enter
the nucleus to activate transcription of IL-12 [10,75] (Fig. 1). Since
IL-12 secreted from activated dendritic cells promotes differentiation
of Th1 cells [76], RIP of TNFαmaybe required for the antiviral immunity
mediated by Th1 cells. However, this hypothesis has not been tested in
vivo.
SPPL2a/b and SPPL3 were also reported to cleave the 18-kDa leader
peptide of the foamy virus envelope protein (LP18) [77]. While
SPPL2a/b catalyzes the intramembrane proteolysis, SPPL3 in this
case may catalyze the primary cleavage that removes bulk of the
LP18 at the luminal side [77]. The functional signiﬁcance of this RIP
reaction has not been identiﬁed.
4. Conclusion
RIP has been identiﬁed as one of the major signaling pathways
that mediate virus–host interactions. Viruses can hijack the pathwayLipid
Droplet
SPP
polyprotein in the ER lumen immediately after the signal peptide-like transmembrane
cleave in the middle of the transmembrane domain so that the mature core protein can
2931J. Ye / Biochimica et Biophysica Acta 1828 (2013) 2926–2932to facilitate progression of their life cycle. They can use the
intramembrane protease such as SPP to process the viral polyprotein,
and to evade immune system by cleaving cellular transmembrane pro-
teins critical for antiviral immunity. On the other hand, RIP is crucial for
host to orchestrate antiviral responses, either directly by combating
viral infection in virus-infected cells, or indirectly by regulating the
functions of lymphocytes and leukocytes. In order to establish success-
ful infection, viruses encode viral proteins to inhibit these antiviral
responses. Understanding this Yin and Yang side of RIP may lead to
new strategies to combat viral infection.Abbreviation
ATF6 activation transcription factor 6
CREB3 cAMP response element binding protein 3
CREB3L1 CREB3-like 1
ER endoplasmic reticulum
HCMV human cytomegalovirus
HCV hepatitis C virus
HIV human immunodeﬁciency virus
HPV human papillomavirus
HSV herpes simplex virus
RIP regulated intramembrane proteolysis
S1P Site-1 protease
S2P Site-2 protease
SPP signal peptide peptidase
SPPLs SPP-like proteins
SREBPs sterol response element binding proteins
TNFα tumor necrosis factor αAcknowledgement
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